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ABSTRACT 
 Lithium, still the gold standard in the 
treatment of bipolar disorder has been proposed 
to inhibit inositol monophosphatase (IMPase) 
and is hypothesized to exert its therapeutic 
effects by attenuating phopshatidylinositol (PI) 
cell signalling. Drug discovery efforts focused 
on small molecule lithium mimetics that 
specifically inhibit IMPase and therefore 
would not exhibit lithium’s undesired side 
effects. One very potent and specific IMPase 
inhibitor is L-690,330. L690,330 was 
developed by Merck Sharp & Dome and is a 
competitive substrate-based inhibitor. We were 
interested in determining the exact binding 
mechanism of L-690,330 to make path for 
future structure-based drug discovery 
approaches. We firstly report here the X-ray 
crystallographic structure of IMPase in 
complex with L690,330. Additionally, we co-
crystallized IMPase with its substrate Ins1P 
and observe movement of a mobile loop that 
was yet not reported. 
 
 
Bipolar disorder is a disabling mental 
illness that is characterized by episodes of both 
elevated or irritable mood (hypomania or 
mania) and decreased energy and activity 
(depression) (1–3). It is estimated to have an 
overall lifetime prevalence of 2.4 % (4) and 
causes annual costs to societies in the range of 
billions (5, 6). Lithium still remains after six 
decades of usage (7) the first line choice for the 
treatment, prevention and prophylaxis of 
bipolar disorder, as it shows reduced relapses 
of both manic and depressive phases (8, 9) and 
is also the only known agent that reduces the 
suicide risk of patients (10, 11). Unfortunately, 
lithium has a problematic side effect profile. 
Lithium’s very narrow therapeutic window (0.5 
– 0.8 mmol/l) makes overdosing and 
intoxication easy and side effects even at 
proper usage can be severe. Side effects include 
nausea, diarrhea, tremor, weight gain, thyroid 
enlargement, diabetes insipidus and renal 
failure (12–18).  
Lithium’s mechanism of action still 
remains elusive. Lithium is a small cation that 
non-specifically interacts with many different 
targets, such as ion channels, enzymes and 
transporters and influences signalling cascades 
and neurotransmission (19). With such a range 
of actions, it has proved difficult (to 
impossible) to define lithium’s mechanism of 
action and which interactions are responsible 
for its therapeutic effects as well its side 
effects. The lithium ion (Li+) has a similar 
hydrated radius to the magnesium ion (Mg2+) 
and has therefore the ability to compete with 
magnesium (20, 21). Magnesium is an 
important cofactor for many enzymes and a 
few magnesium-dependent enzymes that are 
inhibited by lithium at therapeutic 
concentrations (0.6 – 1 mM) are documented. 
One of these enzymes is inositol 
monophosphatase (IMPase) (22).  
IMPase (EC 3.1.3.25) is a highly 
conserved enzyme that hydrolyses inositol 
monophosphate to free inositol and phosphate 
in the phosphatidylinositol (PI) signalling 
cascade (23). The PI pathway is primarily 
activated by G proteins (Gi/o, Gq) that increase 
phospholipase C (PLC) activity. PLC 
hydrolyses phosphatidylinositol 4,5-
bisphosphate (PIP2) to inositol 1,4,5-
trisphosphate (IP3) and diacylgylcerol (DAG). 
Binding of IP3 to the IP3-receptor (IP3-R) 
releases intracellular stored calcium into the 
cytoplasm, while DAG activates protein kinase 
C (PKC). Moreover, IP3 is converted by 
different kinases and phosphatases to a variety 
of inositol phosphates that are involved in 
intracellular signalling. PIP2 is regained mainly 
by recycling of IP3. Different phosphatases 
sequentially dephosphorylate IP3 to free 
inositol that is then reused by different 
enzymes to generate phosphatidylinositol (PI), 
phosphatidylinositol phosphate (PIP) and PIP2 
(24–27). IMPase is the last and rate-limiting 
phosphatase in the recycling of PIP2 and hence 
is a crucial enzyme in the PI cycle. Inhibition 
of IMPase by lithium led to Berridge’s 
“Inositol Depletion Hypothesis” in which 
attenuation of PI signalling is a result of 
inositol depletion and in turn leads to impaired 
PI recycling and production (28). 
IMPase therefore remains an 
interesting therapeutic target for bipolar 
disorder. Great effort in finding and developing 
small molecule IMPase inhibitors was made in 
the 1990s by Merck Sharp & Dohme who 
synthesized potent substrate based inhibitors 
such as L-690,330 and L-693,369 (29). 
Unfortunately, most of these compounds 
showed low bioavailability (30). Nevertheless, 
the esterified prodrug L-690,488 had 
favourable penetrability and mimicked 
lithium’s effect on the PI pathway in human 
cell lines (30). Additionally, 
intracerebroventricular administration of L-
690,330 to mice in form of liposomes 
ameliorated pilocarpine induced behaviour and 
their behaviour in the forced swim test similar 
to mice treated with lithium (31). With 
increasing advancement in drug delivery 
systems, these potent and specific inhibitors 
may gain new interest in the treatment of 
bipolar disorder.  
Surprisingly, no structure-based 
approach was used to date to determine the 
exact binding mechanism of these inhibitors. 
Crystal structures in complex with one of these 
inhibitors would shed light on their exact 
binding mechanism and may provide valuable 
insight for their improvement in potency and 
bioavailability. Here, we firstly report the X-
ray crystallographic structure of human 
IMPase in complex with the potent antagonist 
L-690,330. Moreover, we resolved the 
structure in complex with inositol 1-phosphate 
(Ins1P) and observe movement of a mobile 
loop that was yet not reported and that provides 
strong insight into IMPase catalytic 
mechanism. 
 
RESULTS 
 L-690,330 strongly increases thermal 
stability of IMPase – The potent antagonist L-
690,330 was designed based on the substrate 
Ins1P. Baker et al (32, 33) showed that the 
hydroxyl groups at positions 2 or 6 and 4 are 
important for substrate binding to the enzyme 
while the other hydroxylgroups are not. Based 
on these findings, different inhibitors were 
synthesized that include a phenolic 
bisphosphonate series with L-690,330 having 
one of the highest affinities to IMPase (29). To 
confirm its affinity with published data, the 
inhibitory effect of L-690,330 on IMPase was 
tested using the malachite green assay for 
phosphate detection. Its biochemical 
characterization revealed an inhibitory 
concentration (IC50) of 0.22 ± 0.01 µM (Fig. 
1B) which is in accordance with the literature 
(34).  
Binding of L-690,330 was further 
investigated by differential scanning 
fluorimetry (DSF). At high temperatures most 
proteins destabilize, unfold and expose 
hydrophobic residues. This unfolding is 
monitored in DSF through dyes that bind and 
fluoresce in non-polar environments and the 
melting point Tm of a protein can be calculated. 
Small molecules that bind to the protein often 
stabilize it and shift the melting point to higher 
temperatures (35). IMPase on its own has a 
remarkable melting point of 79°C (Fig. 1B). 
This explains why heat treatment during the 
purification process is possible as 
recommended by McAllister et al (36) without 
denaturing or precipitating the protein. 
Addition of L-690,330 to the reaction mixture 
reveals concentration dependent stabilization 
of IMPase by the inhibitor. At high 
concentrations, the protein melting point is 
shifted by up to 15 °C. In fact, at inhibitor 
concentrations of 30 μM, the melting curve 
cannot be fully visualized (Fig. 1A). 
2-(N-morpholino)ethanolsulfonic acid 
binds to the active site – To compare the 
structural mechanism on how L-690,330 
inhibits IMPase function, we aimed to obtain 
three crystal structures: one structure just in 
complex with its metal cofactors, one in 
complex with the substrate Ins1P and one in 
complex with L-690,330. Primarily 
crystallization attempts indicated that IMPase 
preferably crystallizes in the presence of 
divalent salts (e.g. magnesium, calcium or 
manganese salts), a Good buffer (e.g. MES, Bis 
Tris propane, Tris HCl) and polyethylene 
glycol (PEG) 3350 or 4000. By testing different 
combinations of salt, buffer and PEG, a 
combination of MnSO4 or CaCl2, MES at pH 
5.5 and PEG 4000 turned out to be the most 
promising condition in crystallizing IMPase 
and yielded large and well diffracting crystals. 
Surprisingly, we observed electron 
density for 2-(N-morpholino)ethanolsulfonic 
acid (MES) in the active site of IMPase while 
resolving the enzyme’s structure that was 
aimed to be just with its metal cofactors. The 
crystal with MES diffracted to 1.79 Å 
resolution (Tab. 1) and contains two molecules 
in its asymmetric unit. Both molecules 
assemble as homodimers and show the αβαβα 
core structure that is characteristic for IMPase 
(37). Each monomer holds three manganese 
ions, a MES molecule and a glycerol in its large 
and hydrophilic active site (Fig. 2). Structural 
comparison and superposition with the 
published structure 4AS4 (38) yielded a root-
mean-square-deviation of atomic positions 
(RMSD) of 0.407 Å and shows identical 
location of all metal ions, as well as identical 
orientation of residues that form the pocket. 
Thus, binding of MES seems not to alter the 
shape of the active site or induce movement of 
specific residues. In accordance, activity of 
IMPase in the malachite green assay is not 
affected by MES (data not shown). 
Crystallization with calcium induces 
movement of a mobile loop – Co-crystallization 
of IMPase with its substrate required calcium 
as salt. Calcium inhibits hydrolytic activity of 
IMPase (22) and therefore makes co-
crystallization with Ins1P feasible. Crystals 
with Ins1P only grew when using crystal micro 
seeds that were obtained from previous crystals 
grown in the presence of calcium. Successfully 
grown crystal diffracted to 2.01 Å resolution 
(Tab. 1) and has four identical molecules in one 
cell unit. Each molecule holds one Ins1P 
molecule in the active site and up to three 
calcium ions (three in chain A, two in chain B, 
C and D). Only in chain A electron density is 
clear for all residues. As for the other chains, 
certain regions are disordered and could not be 
modelled. These regions include residues 28-
43 and 73-78 in chain B, 35-37 in chain C and 
30-43, as well as 70-79 in chain D. 
Interestingly, the loop from residues 28-43 that 
forms part of the active site seems to affect 
binding of the third calcium ion and thus, the 
third calcium ion cannot be observed in chain 
B, C and D (Fig. 3).  
Structural alignment (chain A and B) 
with the structure in complex with MES shows 
high similarity (RMSD 0.693 Å) but strikingly 
reveals different orientation of residues 28-43. 
This mobile loop moves away from the active 
site in the crystal structure with Ins1P. More 
specifically, Lys36 is pointing away and no 
longer interacts with other residues that form 
the pocket (Fig. 4B). In the structure co-
crystallized with MES and manganese, Lys36 
interacts with Glu71 via a salt bridge (Fig. 4A).  
The substrate interacts with various 
residues in the active site (Fig. 5A). The inositol 
ring is mainly held by hydrogen bonds that are 
formed in between Glu213 and O4, as well as 
Asp93 and O2 of the sugar ring. Metal ion 
contacts are exclusively formed between the 
calcium ions and the oxygens of the phosphoryl 
group. Detailed and solvent including 
interactions are shown in figure 5A. Protein 
alignment of both resolved structures reveals 
different orientation of the MES sulfonate 
group and the substrate’s phosphoryl group. 
Interestingly, the glycerol in the structure 
resolved with MES and manganese seems to 
mimic the inositol ring (Fig. 5B). Residues that 
are involved in substrate binding however 
show identical conformation in both structures. 
L-690,330 is stabilized by additional 
residues in the pocket – Initial attempts to co-
crystallize IMPase with L-690,330 failed 
because DMSO, in which L-690,330 was 
dissolved, strongly influenced crystal growth 
and only low-quality crystals were obtained. 
Therefore a similar approach as in the previous 
substrate co-crystallization experiment was 
tested by dissolving the inhibitor in the buffer 
IMPase is stored in. Due to the strong 
hydrophilic properties of L-690,330 dissolving 
in storage buffer was easy and co-
crystallization experiments with this stock 
solution yielded well diffracting crystals. 
The crystal diffracted to 1.39 Å 
resolution (Tab. 1) which is the best resolution 
of human IMPase obtained to date. No 
significant secondary structure differences are 
found when comparing to the structure with 
MES. The mobile loops that were partly 
disordered in the structure crystalized in the 
presence of calcium and the substrate are 
ordered and Lys36 is pointing towards the 
pocket. Each chain holds three manganese ions, 
one L-690,330 molecule, as well as several 
glycerol. Interaction of L-690,330 with the 
protein backbone is similar to the substrate. 
One key interaction is the hydrogen bond 
between the para oxygen of the ligand to the 
carboxylate group of Glu213. All three 
manganese ions interact with the phosphonate 
groups of the inhibitor and the extra phosphoryl 
group of L-690,330 interacts with additional 
residues Trp219 and Asp220 which is likely to 
contribute to the strong binding of the inhibitor 
to the pocket (Fig. 6). 
 
DISCUSSION 
 Other crystallographic studies observed 
up to three magnesium or manganese binding 
sites in human IMPase (38, 39), however, no 
studies reported binding of MES buffer to date. 
Also binding of MES does not seem to be 
strong (it is easily outcompeted by lower 
concentrations of inositol 1-phsophate and L-
690,330 in the other crystallization conditions) 
and does not affect the enzyme’s catalytic 
activity, here resolved structure underlines that 
IMPase’s active site is very large (larger than 
necessary to accommodate the substrate). This 
makes it possible for IMPase to hydrolyse a 
variety of other substrates (40–43). 
Interestingly, the MES molecule does not 
orientate like the substrate or substrate mimetic 
L-690,330 in the active site but instead fills in 
other parts of the pocket. This observation 
could potentially be utilized to design novel 
IMPase inhibitors that do not mimic the 
substrate but instead take advantage of the 
large pocket and bind to different residues.  
The crystal structures of IMPase in 
complex with Ins1P and the substrate mimetic 
L-690,330 give invaluable insight into IMPase 
catalytic function. Especially the structure co-
crystallized with Ins1P and calcium and its 
unique structural features that are not reported 
in any other published structure to date. The 
mobile loop that is formed by residues 28-43 
and that is only observed in chain A of the 
crystal structure takes in an “open” 
conformation with Lys36 pointing away from 
the pocket. Movement of Lys36 is interesting 
in this regard as it seems to be involved in the 
catalytic mechanism of IMPase. Mutagenic 
studies by Ganzhorn et al. (44) in which Lys36 
was mutated to Gln36 showed a decrease in 
IMPase’s turnover of the substrate. Suggestive 
is that Lys36 increases the polarizing effect of 
one of the metal ions by interacting with Glu70 
or Glu71. This would decrease the negative 
charge of the glutamate residues to which the 
magnesium ion is exposed and thus would 
induce hydrolysis of the substrate (44). 
Different conformations of the mobile loop 
were also observed in the homologue of 
Archaeoglobus fulgidus. It was proposed that 
the mobility of this loop is associated with 
metal and/ or substrate binding and is important 
for product release (45). Identical role in the 
human form should not be excluded.  
Other structures in complex with Ins1P 
are described. 1IMA and 1IMB were co-
crystallized with D-myo-Ins1P and gadolinium 
and L-myo-Ins1P and gadolinium respectively 
(46). Moreover, Ganzhorn et al. (47) deposited 
IMPase in complex with the substrate and 
calcium (1AWB). Structural alignment of here 
resolved structure with 1AWB reveals same 
orientation of all calcium ions, as well as the 
substrate, however, Lys36 points towards the 
active site in the deposited structure. This 
observation was surprising to us as we 
hypothesized that calcium somehow exerts its 
influence on the mobile loop that ultimately 
leads to its distinct conformation. As calcium is 
found in the active site of 1AWB it must also 
be for other reason than calcium that Lys36 
points away in here resolved structure. Any 
influence of the crystal symmetry should not be 
disregarded. It remains unclear why the mobile 
loop did not crystalize identical to published 
structures such as in 1AWB or 4AS4 and is 
rather disordered in certain chains instead of 
taking in energetically favourable 
conformation (i.e. Lys36 towards the active 
site). Nevertheless, here resolved crystal 
structure provides a “snapshot” of its 
movement that can explain on how calcium 
may exert its inhibitory effect on IMPase. 
Lastly, IMPase in complex with L-
690,330 is described with the highest 
resolution available to date. Superimposition 
with the structure in complex with MES 
revealed no structural differences in between 
the pockets and alignment with the structure 
co-crystallized with the substrate emphasizes 
that L-690,330 mimics the substrate. As L-
690,330 is essentially a non-hydrolysable 
substrate, the crystal structure in complex with 
this inhibitor confirms that the mobile loop 
containing Lys36 orientates towards the active 
site when binding the substrate and activating 
manganese.  
Our structural findings strongly suggest 
movement of the mobile loop in the course of 
catalysis. As observed by Ganzhorn et al. (44), 
two segments of the active site appear to 
undergo structural changes upon substrate and 
metal binding. These segments comprise 
residues 30-40 and 70-75. The latter segment 
was observed to be partly disordered in the 
structure here crystallized with Ins1P and was 
previously shown to move away from the 
cation binding site in the apo enzyme structure 
(39). These two segments might approach each 
other for catalysis and Lys36 through salt 
bridge interactions with Glu70 and/or Glu71 
would facilitate their approach. 
 
 
EXPERIMENTAL PROCEDURES 
 Materials – All materials were 
purchased from Sigma-Aldrich or Fisher 
Scientific and were the highest purity available 
if not stated otherwise. Ampicillin was 
purchased from Melford and L-690,330 from 
Tocris Bioscience. 
 Preparation of human recombinant 
IMPase – Human cDNA for full length IMPase 
with an amino terminal 6 histidine tag and 3C 
protease cleavage site was synthesized and 
subcloned into a pET15b vector by 
GenScript®. Expression of recombinant 
human IMPase was described elsewhere (38). 
Hence, transformed Escherichia Coli 
Rosetta2(DE3) cells (Merck Millipore) were 
grown in Luria-Bertani (LB) broth containing 
50 µg/mL ampicillin and 35 µg/mL 
chloramphenicol overnight at 37°C and 200 rev 
min-1. Cells from this culture were used to 
inoculate LB broth containing 2.5 mM betaine, 
660 mM sorbitol, 50 µg/mL ampicillin and 35 
µg/mL chloramphenicol and grown at 37°C 
until the OD600 reached 0.2-0.3. The 
temperature was decreased to 25°C and cells 
further incubated until the OD600 reached 0.6. 
Protein expression was induced by the addition 
of 0.4 mM isopropyl-β-D-
thiogalactopyranoside (IPTG) and the culture 
was left overnight at 180 rev min-1 and 25°C. 
Bacterial cells were harvested by 
centrifugation at 9600 x g for 20 min at 4°C and 
resuspended lysis buffer (20 mM Tris-HCl pH 
7.8, 150 mM NaCl, 40 U/mL DNAse I (Sigma-
Aldrich) and 1 EDTA-free protease inhibitor 
tablet (Thermo Scientific) per 50 mL). The 
pellet was lysed by ultrasonication and the 
soluble protein separated by centrifugation at 
33000 x g for 20 min at 4°C. The supernatant 
was heat treated at 68°C for 1 h and the 
precipitated protein was pelleted by 
centrifugation at 32816 x g for 20 min at 4°C. 
The supernatant was then incubated at 4°C for 
1 h with TALON superflow resin (GE 
Healthcare) that was pre-equilibrated with 
binding buffer (20 mM Tris-HCl pH 7.8, 150 
mM NaCl, 10 mM imidazole). After 
incubation, the resin was washed with wash 
buffer (20 mM Tris-HCl pH 7.8, 150 mM 
NaCl, 15 mM imidazole) and the protein eluted 
with elution buffer (20 mM Tris-HCl pH 7.8, 
150 mM NaCl, 250 mM imidazole). Elution 
fractions were pooled and the 6 histidine tag 
cleaved overnight at 4°C by the addition of 
PreScission protease (see below) at a protease-
to-protein ratio 1:100 (w/w). After digestion, 
PreScission protease was separated from the 
target protein by incubating the digestion 
mixture with Glutathione Fast 4 flow resin (GE 
Healthcare) that was pre-equilibrated with size 
exclusion chromatography (SEC) buffer (20 
mM Tris-HCl pH 7.8, 150 mM NaCl). The 
collected flow through was concentrated to 
approximately 5 mL using viva spin 
concentrators (Sartorius Stedim) at 4000 x g 
and 4°C and applied on a with SEC buffer 
equilibrated gel filtration column (HiLoad 
16/600 Superdex 75 prep grade, GE 
Healthcare) using the ÄKTA FPLC system 
from GE Healthcare. Protein was eluted at a 
flow rate of 2.5 mL/min and fractions analysed 
by SDS PAGE using NuPAGE® Novex® 4-
12% Bis-Tris protein gels (life technologies). 
Fractions containing the protein were pooled, 
concentrated and re-buffered into storage 
buffer (20 mM Tris-HCl pH 7.8, 150 mM 
NaCl, 1 mM EDTA, 10 % glycerol (v/v)) using 
viva spin concentrators at 4000 x g and 4°C. 
 Preparation of PreScission protease – 
Glutathione S-transferase (GST) tagged HRV 
3C protease (PreScission protease) cloned into 
a pGEX-1 vector was used to transform 
Rosetta2(DE3) cells. Transformed cells were 
used to inoculate a pre-culture of LB broth 
supplemented with 50 µg/mL ampicillin and 35 
µg/mL chloramphenicol and grown overnight 
at 37°C and 200 rev min-1. Cells were used the 
next day to inoculate the main culture using the 
same broth and antibiotics and grown at 180 
rev min-1 until reaching an OD600 of 
approximately 0.6. Flasks were put on ice for 
15 min, induced with 0.2 mM IPTG and grown 
overnight at 20°C and 180 rev min-1. The next 
day, cells were harvested by centrifugation at 
9600 x g for 20 min at 4°C and resuspended 
lysis buffer (50 mM Tris-HCl pH 8.0, 1000 
mM NaCl, 1 mM EDTA, 1 mM DTT) and 
lysed by ultrasonication. Soluble protein was 
separated by centrifugation at 33000 x g for 20 
min at 4°C and the supernatant applied on a 
with lysis buffer pre-equilibrated GST Trap FF 
column (GE Healthcare). The column was 
extensively washed with lysis buffer and 
protein eluted with 10 mM reduced glutathione 
in lysis buffer. Fractions were analysed by SDS 
PAGE as described above and protein 
containing fractions pooled and dialyzed 
overnight into storage buffer (50 mM Tris-HCl 
pH 8.0, 150 mM NaCl, 10 mM EDTA, 1 mM 
DTT, 20 % (v/v) glycerol). 
 Malachite green assay and DSF – The 
inhibitory effect of L-690,330 was tested using 
the malachite green assay (48–50). A 10-point 
dose response curve was recorded to determine 
L-690,330’s inhibitory concentration (IC50). 
For this, L-690,330 (30 µM highest 
concentration) was added to 0.08 ng/µL 
IMPase in assay buffer (50 mM Tris-HCl pH 
7.4, 3 mM MgCl2, 150 mM KCl, 0.5 mg/mL 
bovine serum albumin (BSA), 0.01 % (w/v) 
Triton X-100) and incubated at room 
temperature for 10 min. Then, 0.075 mM 
inositol 1-phosphate was added, incubated at 
37°C for 30 min and the reaction stopped and 
phosphate formation detected by adding 
BIOMOL GREEN solution (Enzo life science). 
The plate was incubated at room temperature 
for 30 min and the absorbance then measured 
at λ= 630 nm on the PHERAstar FS plate reader 
(BMG labtech). Data was analyzed and plotted 
with PRISM 7.0.2 (GraphPad). 
To determine the melting points of 
IMPase in the presence of L-690,330, the 
inhibitor (30 µM highest concentration) was 
mixed with 6 µM IMPase in DSF assay buffer 
(50 mM HEPES pH 7.4, 3 mM MgCl2, 150 mM 
KCl, 1 mM EGTA) and incubated at room 
temperature for 10 min. Then 4 x SYPRO 
Orange dye (Sigma-Aldrich) was added and 
melting curves were recorded on the 
LightCylcer 480 II (Roche). To determine the 
enzyme’s melting point on its own, IMPase at 
different concentrations in DSF buffer was 
mixed with 4 x SYPRO Orange dye and the 
melting curve directly recorded. Integration 
time was set manually to 1 sec. The 
temperature was hold at 20°C for 1 min and 
then increased by 1°C every 0.4 min up to a 
maximal temperature of 95°C. Data was 
integrated and analysed using the LightCycler 
480 SW 1.5 program (Roche); melting points 
were determined manually. 
 Crystallization – Crystallization of 
human IMPase was carried out on VDX plates 
(Hampton research) using the hanging drop 
method or 2 well MRC plates (Swissci) using 
the sitting drop method. 
To crystallize human IMPase in the 
presence of manganese, equal volumes (1 μL) 
of the target protein in storage buffer (20 
mg/mL) and reservoir solution (0.12 M 
MnSO4, 0.1 M MES pH 5.5, 24 % (w/v) PEG 
4000) were mixed and incubated at room 
temperature for a few days. 
Human IMPase in complex with the 
potent inhibitor L-690,330 was crystallized at 
room temperature using the hanging-drop 
method and micro seeding. Seeds were 
obtained from crystals described above using 
the Seed Bead kit from Hampton research. 
Human IMPase in storage buffer (20 mg/mL) 
was firstly incubated at 37°C for 15 min in the 
presence of 5 mM L-690,330 that was 
previously dissolved in storage buffer. Then, 
equal volumes (1 μL) of the enzyme-inhibitor 
mix and reservoir solution (0.2 M MnSO4, 0.1 
M MES pH 5.5, 25 % (w/v) PEG 4000) 
containing seeds (diluted 1:100 in reservoir 
solution) were mixed and incubated at room 
temperature for a few days. 
Human IMPase in complex with the 
substrate was crystallized at room temperature 
using the sitting-drop method and micro 
seeding. Seeds were obtained from crystals 
grown in the presence of CaCl2. For this, equal 
volumes (1 µL) of human IMPase in storage 
buffer (20 mg/mL) and reservoir solution (0.2 
M CaCl2, 0.1 M MES pH 5.5, 25 % (w/v) PEG 
4000) were mixed and incubated at room 
temperature for a few days. Formed crystals 
were used to produce crystal micro seeds using 
the Seed Bead kit from Hampton research. To 
co-crystallize human IMPase with inositol 1-
phosphate, human IMPase in storage buffer (20 
mg/mL) was incubated at 37°C for 8 min in the 
presence of the substrate (8 mM, dissolved in 
water). Then, equal volumes (1 µL) of the 
enzyme-substrate mix and reservoir solution 
(0.2 M CaCl2, 0.1 M MES pH 5.5, 25 % (w/v) 
PEG 4000) containing seeds (diluted 1:100 in 
reservoir solution) were mixed and incubated at 
room temperature for a few days. 
All crystals were transferred from 0 to 
30 % (v/v) glycerol in steps of 10 % prior to 
flash cooling in liquid nitrogen and data 
collection. X-ray diffraction data was collected 
at the Diamond Light Source (Oxfordshire, 
United Kingdom) on the I04 beamline (λ = 
0.9795 Å) using a Dectris Pilatus 6M-F 
detector. The crystals were cooled at 100 K 
during data collection by a Cryostream (Oxford 
Cryosystems Ltd). Data were integrated and 
scaled using the automatic Xia2 processing at 
the Diamond Light Source. 
Part of the structures were initially 
solved by molecular replacement using 
previously determined structures. For the 
structure with manganese and MES in the 
active site a published structure of human 
IMPase (PDB 4AS4) was used in the usual 
spacegroups (P 32 2 1). For the structure in 
complex with L-690,330, the refined structure 
with manganese and MES in the active site was 
used as a model. For the structure in complex 
with inositol 1-phosphate, a structure that was 
crystallized in the presence of calcium in our 
laboratories was used as a model (not 
disclosed). 
Data was processed with CCP4 (51), 
Phenix (52) and Buster (53) and manual 
rebuilding was performed in Coot (54). All 
pictures and operations were conducted in 
Maestro version 10.6 (Schrödinger). Before 
analysis, protein structures were prepared using 
Maestro’s integrated protein preparation 
wizard: Bond orders were assigned, hydrogens 
were added, zero-order bonds to metals and 
disulfide bonds were created, as well as water 
beyond 5 Å from hetero groups were deleted. 
Moreover, the protein was refined by assigning 
hydrogen bonds at pH 7.0. Interaction diagrams 
were manually plotted with ChemDraw Prime 
15.1 (PerkinElmer).
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FIGURE LEGENDS 
 
FIGURE 1. Dose response of L-690,330 in the malachite green and DSF assay. A, dose dependent 
effect of L-690,330 on IMPase melting point is shown. L-690,330 stabilizes IMPase and increases 
melting point in a concentration dependent fashion. Data is expressed as the mean of two 
independent experiments and standard deviation is represented by the filled area or error bars. B, 
dose response of L-690,330 in the malachite green assay. An IC50 of 0.22 ± 0.01 µM (n= 3) was 
determined. Data is expressed as mean of three independent experiments; standard deviation is 
represented by the error bars 
 
FIGURE 2. Active site of IMPase co-crystallized with manganese and MES. MES exclusively 
interacts with the three manganese ions (Mn1, Mn2 and Mn3) via its sulfonic moiety and no 
interaction to other pocket residues is seen. 
 
FIGURE 3. Comparison of chain A and chain B of IMPase crystallized in the presence of calcium 
and Ins1P. Electron density for all residues is seen in chain A while residues 28-43 and 73-78 in 
chain B could not be resolved and missing residues are indicated by the dotted line. 
 
FIGURE 4. Mobile loop. A, the loop comprised of residues 28-43 is directed towards the active 
site in the crystal structure of IMPase crystallized in the presence of manganese and MES. Lys36 
points inwards and forms a salt bridge with Glu71, as well as a hydrogen bond with a conserved 
water that is coordinated to the third manganese Mn3. B, this same mobile loop takes in an 
outwards pointing conformation in the structure co-crystallized with calcium and Ins1P. Lys36 
points away and does not form part of the pocket. 
 
FIGURE 5. Active site of IMPase co-crystallized with calcium and Ins1P. A, key interactions of 
Ins1P with IMPase are the metal coordinating bonds to the phosphoryl group and the hydrogen 
bond of the inositol ring to Glu213, as well as hydrogen bonds to backbone residues Gly96 to 
Thr96. B, superimposition of both resolved crystal structure is shown. The manganese and calcium 
metal ions coordinate identically in the active site of both structures. A glycerol found in the 
structure with manganese takes in the space of the inositol ring and forms identical hydrogen bonds 
to Ala196 and Glu213. 
 
FIGURE 6. L-690,330 in the active site of IMPase. L-690,330 takes in identical orientation as the 
substrate. The bisphosphonate group rigorously forms metal bonds with all manganese ions (Mn1, 
Mn2 and Mn3), as well as additional hydrogen bonds to backbone residues Trp219 and Asp220 
that are not observed with the substrate Ins1P. 
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TABLE 1. 
 
 IMPase with manganese and MES 
IMPase with 
calcium and Ins1P 
IMPase with manganese 
and L-690,330 
Wavelength (Å) 0.9795 0.9141 0.9141 
Resolution range (Å) 42.47 - 1.73 (1.792 - 1.73) 
20.21 - 1.68 (1.74 - 
1.68) 20.35 - 1.39 (1.44 - 1.39) 
Space group P 3221 P 1 P 3221 
Unit cell: a, b, c (Å) 84.94, 84.94, 152.51 56.92, 61.57, 76.3 85.29, 85.29, 151.51 90, 90, 120 87, 87.17, 80.34 90, 90, 120 
Total reflections 132014 (12971) 294100 (29110) 654228 (63759) 
Unique reflections 67052 (6585) 112520 (11159) 128391 (12704) 
Multiplicity 2.0 (2.0) 2.6 (2.6) 5.1 (5.0) 
Completeness (%) 99.88 (99.91) 96.90 (95.63) 99.88 (99.90) 
Mean I/sigma(I) 17.57 (2.34) 8.73 (2.11) 12.13 (2.43) 
Wilson B-factor 21.55 20.30 12.35 
R-merge 0.03154 (0.3805) 0.06425 (0.3999) 0.07519 (0.5912) 
R-meas 0.04461 0.08021 0.08399 
CC1/2 0.999 (0.7) 0.995 (0.828) 0.998 (0.782) 
CC* 1 (0.908) 0.999 (0.952) 0.999 (0.937) 
R-work 0.1712 (0.2863) 0.2160 (0.2896) 0.1459 (0.2335) 
R-free 0.2100 (0.3030) 0.2501 (0.3252) 0.1647 (0.2456) 
Number of non-
hydrogen atoms 4797 8256 5141 
macromolecules 4222 7802 4307 
ligands 66 97 157 
water 509 357 677 
Protein residues 548 1049 550 
RMS(bonds) 0.007 0.007 0.015 
RMS(angles) 1.12 1.11 1.72 
Ramachandran 
favored (%) 98 98 98 
Ramachandran outliers 
(%) 0 0.38 0 
Clashscore 6.69 4.72 3.90 
Average B-factor 25.80 26.90 19.60 
macromolecules 24.40 26.70 16.90 
ligands 31.80 30.90 26.80 
solvent 36.00 30.90 35.30 
 
